Axon Enterprise (NASDAQ:AXON) PT Raised to $233.00 at Raymond James

Axon Enterprise (NASDAQ:AXON) had its price objective raised by Raymond James from $223.00 to $233.00 in a research report report published on Wednesday morning, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on the stock. Northland Securities lifted their price target on shares of Axon Enterprise from $227.00 to $235.00 and gave the company an outperform rating in a research report on Friday, August 11th. Morgan Stanley began coverage on shares of Axon Enterprise in a research report on Tuesday, August 22nd. They set an equal weight rating and a $230.00 target price on the stock. Needham & Company LLC reissued a buy rating and set a $240.00 target price on shares of Axon Enterprise in a research report on Wednesday, August 9th. StockNews.com assumed coverage on shares of Axon Enterprise in a report on Thursday, October 5th. They issued a hold rating on the stock. Finally, Barclays cut their price target on shares of Axon Enterprise from $256.00 to $239.00 and set an overweight rating on the stock in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and an average target price of $245.64.

Axon Enterprise Stock Up 1.0 %

Shares of NASDAQ:AXON opened at $217.94 on Wednesday. The stock has a market cap of $16.33 billion, a P/E ratio of 111.76 and a beta of 0.85. The firm has a fifty day moving average price of $208.36 and a 200 day moving average price of $199.78. The company has a debt-to-equity ratio of 0.44, a current ratio of 3.15 and a quick ratio of 2.98. Axon Enterprise has a 1-year low of $162.39 and a 1-year high of $231.71.

Insider Transactions at Axon Enterprise

In other news, President Joshua Isner sold 29,699 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $196.37, for a total transaction of $5,831,992.63. Following the completion of the transaction, the president now owns 356,489 shares in the company, valued at $70,003,744.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Julie A. Cullivan sold 515 shares of the stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $214.47, for a total value of $110,452.05. Following the completion of the transaction, the director now owns 5,367 shares in the company, valued at approximately $1,151,060.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Joshua Isner sold 29,699 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $196.37, for a total transaction of $5,831,992.63. Following the completion of the transaction, the president now owns 356,489 shares of the company’s stock, valued at approximately $70,003,744.93. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently bought and sold shares of AXON. Capital International Investors lifted its holdings in Axon Enterprise by 605.2% in the 1st quarter. Capital International Investors now owns 2,660,634 shares of the biotechnology company’s stock valued at $366,449,000 after acquiring an additional 2,283,343 shares during the last quarter. Sands Capital Management LLC lifted its holdings in Axon Enterprise by 101.6% in the 2nd quarter. Sands Capital Management LLC now owns 1,993,126 shares of the biotechnology company’s stock valued at $388,899,000 after acquiring an additional 1,004,556 shares during the last quarter. BlackRock Inc. lifted its holdings in Axon Enterprise by 11.7% in the 1st quarter. BlackRock Inc. now owns 8,329,479 shares of the biotechnology company’s stock valued at $1,872,883,000 after acquiring an additional 870,481 shares during the last quarter. Norges Bank acquired a new stake in Axon Enterprise in the 4th quarter valued at about $102,920,000. Finally, Geode Capital Management LLC lifted its holdings in Axon Enterprise by 57.3% in the 2nd quarter. Geode Capital Management LLC now owns 1,583,100 shares of the biotechnology company’s stock valued at $308,281,000 after acquiring an additional 576,420 shares during the last quarter. Institutional investors own 76.52% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.